Larazotide Peptide
Cholera taught researchers how the gut's tight junctions swing open. Larazotide is the counter-move, and its phase 3 stopped for futility in 2022. The whole arc is on this page.
Choose your pack
For research use only. Not for human or veterinary use.
What Larazotide Peptide is
The plain-language version, first.
Larazotide is an eight amino acid peptide with the sequence GGVLVQPG, also known as larazotide acetate or AT-1001, that acts on the surface of the intestinal lining to promote tight junction assembly and oppose zonulin driven permeability. It was designed not to be absorbed into the bloodstream, has been studied orally in celiac disease through phase 2 and phase 3 trials, and is not approved by any regulator.
This compound's origin story starts with cholera, which is not a sentence you get to write often. Studying how cholera toxin loosens the gut wall taught researchers something basic: the junctions between gut cells are not welds. They are gates, actively managed, with signalling that opens and closes them. > A pathway called zonulin emerged as one of the gate-openers. Larazotide was built as the counter-move: eight residues designed to keep the gates from swinging open. The target application was coeliac disease, where gate management goes wrong in a well-documented way. A clean mechanism aimed at a real disease with a defined patient population. _On paper, one of the best-motivated compounds on this shelf. The paper is not where it ended._
What is larazotide?
Mechanism studied, not outcome promised.
Acts on the luminal surface, promoting junction assembly and blocking the actin rearrangement that opens paracellular gaps.
The lactulose to mannitol permeability ratio. Two phase 2 trials used it as primary. Both failed to hit it.
Think of the gut lining as a nightclub with a rope line between every pair of bouncers. The ropes are tight junctions.
Zonulin signalling is somebody convincing the bouncers to unhook them. > Larazotide was designed to be the manager who walks the line re-hooking ropes. As pharmacology goes this is unusually concrete.
A defined pathway, a measurable outcome in permeability, a coherent short-acting local mechanism in the gut rather than anything systemic. The mechanism was never really the argument.
The clinical results were. Here's the honest part, and it is the same sentence this whole category keeps teaching. _A beautiful mechanism is a hypothesis wearing a suit.
The trial is still the interview._
The research so far for Larazotide Peptide
Where the evidence is thin, we say so.
Leffler 2015, 342 patients: the 0.5 milligram dose met its symptom primary endpoint. Roughly 630 patients studied across phases 1 and 2.
Both permeability primary endpoints. The 1 mg and 2 mg doses in the 2015 trial. The phase 3. And the dose-response, which runs backwards across every trial.
CedLara, NCT03569007, targeted 525 patients. On 21 June 2022 at roughly 262 enrolled, the independent statistician found the additional patients needed to show a difference were too many to justify continuing. 9 Meters Biopharma filed for bankruptcy thirteen months later with about 152,000 dollars in cash.
This file deserves respect, because it did the thing almost nothing else here did: it went the distance. Multiple phase 2 trials.
A real phase 3 in coeliac disease. Years of properly registered clinical work. > And in 2022 the phase 3 stopped for futility.
The interim data showed it was not going to work, so it stopped. That is the honest end of a serious attempt.
Not fraud, not mismanagement, just a hypothesis that met its test and did not pass. Nothing approved.
Development effectively over. _The most complete clinical arc on this shelf, ending in a clear no. If you want to understand why we hedge every mechanism on every page, this compound is the reason in miniature._
Have a look at the vial sizes we currently keep in stock.
Larazotide Peptide specs
The chemistry, exactly as released.
Who studies Larazotide Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Celiac disease research
The indication the entire programme targeted, in patients still symptomatic on a gluten-free diet. Four trials, roughly 630 patients before phase 3.
Intestinal permeability
Groups using the lactulose to mannitol ratio to quantify paracellular transport. This compound is the reason a lot of that methodology got refined.
Tight junction biology
Zonulin, occludin and the actin cytoskeleton. Larazotide is the first-in-class pharmacological tool for the pathway.
Drug development reviewers
It is a case study in secondary endpoints carrying a programme past a failed primary, and what happens at phase 3 when they do.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Larazotide Peptide backstory
How it got here.
Alba Therapeutics originated the compound and ran the phase 2 programme. It licensed to Innovate Biopharmaceuticals in March 2016, which became 9 Meters Biopharma, which went bankrupt in July 2023.
Along the way there were pivots. A four-patient open-label case series in children with multisystem inflammatory syndrome after COVID reported faster resolution of gastrointestinal symptoms against 22 retrospective historical controls.
The authors themselves wrote that a double-blind randomised placebo-controlled study would be needed to determine efficacy. It is a case series in four children, not evidence of effect.
After the phase 3 futility call, nothing survived.
- 1
Mined from cholera toxin
Screening of synthetic peptides related to Vibrio cholerae zonula occludens toxin found an eight residue stretch matching a sequence in human zonulin.
- 2
A decade of phase 2
Alba Therapeutics, then Innovate, then 9 Meters. Roughly 630 patients. Symptom endpoints improved; permeability endpoints did not.
- 3
Futility, then bankruptcy
Phase 3 halted at interim in June 2022. The sponsor filed for bankruptcy in July 2023. The compound has no active developer.
Buying Larazotide Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
Every human study was oral
This molecule was engineered to stay in the gut lumen and not enter blood. There is no human data for larazotide by any injected route, because injecting it defeats the mechanism it was built around.
Stuff people ask about Larazotide Peptide
If your question is not here, email us. Real human answers.
No. CedLara, NCT03569007, was terminated at interim analysis on 21 June 2022. The sponsor stated that the additional number of patients needed to determine a significant clinical outcome between placebo and larazotide was too large to support trial continuation. The trial was stopped at roughly 262 of a planned 525 patients.
Because it acts on the luminal surface of the intestine, the side facing the gut contents, where the tight junctions it regulates are accessible. Khaleghi and colleagues reported plasma concentrations below the limit of quantification, under 0.05 nanograms per millilitre, at every trial dose tested. Systemic exposure is not the goal and was never achieved.
It was derived from one. Vibrio cholerae produces zonula occludens toxin, which opens intestinal tight junctions. Researchers screening synthetic fragments related to that toxin identified an eight residue sequence near its carboxyl terminus matching a stretch in human zonulin, and developed it as a tight junction regulator.
It runs backwards, and nobody has explained it. In the 2015 trial with 342 patients, 0.5 milligrams met the primary endpoint while 1 and 2 milligrams did not. Across earlier trials different low doses won. Reviewers have called the pattern curious. An inconsistent, inverted dose-response is a reason to be cautious about whether an effect is real.
No. It reached phase 3 and was never approved in any jurisdiction for any indication. I found no orphan designation and no FDA Fast Track designation on the public record. The developing company, 9 Meters Biopharma, filed for bankruptcy in July 2023.
That is four children. An open-label compassionate-use case series compared against 22 retrospective historical controls, reporting faster resolution of gastrointestinal symptoms and faster clearance of spike antigen. The authors wrote that a double-blind randomised placebo-controlled study is needed to determine efficacy. It is a case series, not evidence of effect.
Good pairing options with Larazotide Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Larazotide Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Everything alive builds its peptides from left-handed amino acids. In 1981 a South American tree frog turned up carrying one with a right-handed piece bolted into position two. The whole human record is a single 150-patient trial from 1985.
Found in pig intestine in 1970, then it kept turning up everywhere else: lungs, brain, pancreas, immune cells. Its 461-patient phase 3 stopped for futility, which is a specific word with a specific meaning.
Order Larazotide Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Larazotide Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 20, 2026
People also search for Larazotide Peptide
Other names for the same compound.